Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-341 in Multiple System Atrophy
NCT05526391Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Placebo with TAK-341 (2 arms). Primary endpoint: Modified Unified Multiple System Atrophy Rating Scale Part I Total Score at Week 52. Started Nov 2022; status: completed.
02
Drugs
MEDI1341
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05526391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526391.